Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Cerus Corp

NASDAQ: CERS · Industrial Applications and Services · 3 alerts · CIK 1020214

Share price
$1.86Close, Nov 16
Market cap
$376M
Shares outstanding
201.95MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Cerus Corp filings on SEC EDGAR ↗

4:20 PM ET 10-Q
Financial Results ▶ Call

Cerus Q3 2026 Results: Net Loss of $550K, Loss Widens

For the quarter ended September 30, 2026, Cerus Corporation reported product revenue of $57.7 million, a 9.5% increase over the prior year, and achieved a narrow net loss of $0.6 million. The company significantly reduced its nine-month net loss from $13.5 million in 2025 to $5.2 million in 2026, driven by higher gross profits and lower research and development expenses.

Key figure
Net loss $550K
4:08 PM ET 8-K
Financial Results

Cerus Financial Results

Cerus Corporation reported Q3 2026 total revenue of $64.0 million, driven by 10% year-over-year growth in product revenue to $57.7 million. The company also announced positive topline Phase 3 results for its INTERCEPT Blood System for red blood cells and generated $3.0 million in operating cash flow during the quarter.

Term
Q3 2026

“Our solid performance in Q3 builds upon a strong first half of 2026 and increases our confidence as we approach year-end. Continued growth from our IFC business, core platelet franchise and international INT 200 rollout strengthens our foundation as we work to establish INTERCEPT as the global standard of care.”

Vivek Jayaraman, Cerus’s president and chief executive officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.